Finance

Beta
Lists
UTHR:NASDAQ
United Therapeutics Corp
$549.87
+0.40%
(+2.18) 1D
$554.74
+0.89% (+4.87)
After hours
Closed: Jun 5, 4:00:00 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for UTHR...
Open
$547.10
High
$550.99
Low
$540.80
Mkt. cap
23.34B
Avg. vol.
434.99K
Volume
663.25K
P/E ratio
20.29
52-wk high
$609.35
52-wk low
$272.18
EPS
$27.09
Beta
0.57
Shares outstanding
42.45M
No. of employees
1K
Open
$547.10
High
$550.99
Low
$540.80
Mkt. cap
23.34B
Avg. vol.
434.99K
Volume
663.25K
P/E ratio
20.29
52-wk high
$609.35
52-wk low
$272.18
EPS
$27.09
Beta
0.57
Shares outstanding
42.45M
No. of employees
1K
Analyst outlook
Analyst Ratings
Based on 10 analysts giving stock ratings to UTHR in the past 3 months
Strong Buy
Buy
8
Hold
2
Sell
0
12 month forecast
Based on 10 Wall Street analysts offering 12 month price targets for UTHR in the last 3 months.
Highest
Current $549.87
$738.00 (+34.21%)
Average
$665.90 (+21.10%)
Lowest
$516.00 (-6.16%)
News stories
From sources across the web
Profile
United Therapeutics Corporation is an American biotechnology company that develops pharmaceuticals and technologies related to organ transplantation, including xenotransplantation. Many of the company's products are focused towards lung disease and organ manufacturing. United Therapeutics is co-headquartered in Silver Spring, Maryland and Research Triangle Park, North Carolina, with additional facilities in Magog and Bromont, Quebec; Melbourne and Jacksonville, Florida; Blacksburg, Virginia; and Manchester, New Hampshire. Wikipedia
About United Therapeutics Corp
CEO-
Employees1.4K
Founded1996
HeadquartersSilver Spring, Maryland, United States
SectorBiotechnology
Websiteunither.com
Last report
May 6, 2026
Fiscal period
Q1 2026
EPS / Est. (USD)
$5.82 / $7.04
-17.38%miss
Revenue / Est. (USD)
781.50M / 797.38M
-1.99%miss
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
798.60M
799.50M
790.20M
781.50M
Cost of goods sold
87.60M
100.90M
103.40M
133.40M
Cost of revenue
87.60M
100.90M
103.40M
133.40M
Research and development expenses
134.00M
127.50M
139.50M
138.20M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
190.80M
181.80M
189.90M
184.10M
Operating expense
324.80M
309.30M
329.40M
322.30M
Total operating expenses
412.40M
410.20M
432.80M
455.70M
Operating income
386.20M
389.30M
357.40M
325.80M
Other non operating income
3.90M
300.00K
800.00K
15.30M
EBT including unusual items
408.40M
438.00M
444.00M
318.30M
EBT excluding unusual items
434.10M
433.00M
398.30M
379.90M
Income tax expense
98.90M
99.30M
79.70M
43.40M
Effective tax rate
24.22%
22.67%
17.95%
13.63%
Other operating expenses
-
-
-
-
Net income
309.50M
338.70M
364.30M
274.90M
Net profit margin
38.76%
42.36%
46.10%
35.18%
Earnings per share
6.41
7.16
7.70
5.82
Interest and investment income
51.30M
46.40M
43.20M
41.80M
Interest expense
-7.30M
-3.00M
-3.10M
-3.00M
Net interest expenses
44.00M
43.40M
40.10M
38.80M
Depreciation and amortization charges
-
-
-
-
EBITDA
407.30M
411.20M
380.20M
348.40M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer